Leukemia & Lymphoma Society Academic Clinical Trials Program
Closing Date: 28/10/2022
Funding for clinical trials in hematological malignancies and related pre-malignant conditions with the aim of developing innovative approaches to treatment.
The Leukemia & Lymphoma Society (LLS) funds cutting-edge research around the world for every type of blood cancer, including leukemia, lymphoma, myeloma, and other rare types of blood cancers.
The Academic Clinical Trials Program (ACT) is a new program intended to enhance the development and implementation of academic investigator initiated clinical trials (IIT) in the hematological malignancy space.
Applications are sought proposing novel approaches to the treatment of hematological malignancies and related pre-malignant conditions. The primary focus will be IIT Phase 1 or 2 trials investigating novel agents in any hematological disease either as single agents or in combination therapies. Any therapy type whether biological or chemical is eligible. The focus of the research must be a clinical trial; although additional aims can address topics such as correlative studies, biomarker investigations, biomarker validation etc. Repurposing of existing agents into novel diseases will also be considered, as will existing trials or expansion of existing trials.
The start date for ACT grants is 1 July 2023.
|Funding body||Leukemia & Lymphoma Society (LLS)|
|Maximum value||1,000,000 USD|
|Fund or call||Fund|